Anebulo Pharmaceuticals Inc (ANEB)
2.05
+0.09
(+4.59%)
USD |
NASDAQ |
Sep 27, 16:00
2.105
+0.06
(+2.68%)
After-Hours: 20:00
Anebulo Pharmaceuticals Research and Development Expense (Annual): 3.549M for June 30, 2024
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| June 30, 2024 | 3.549M |
| June 30, 2023 | 5.600M |
| Date | Value |
|---|---|
| June 30, 2022 | 2.962M |
| June 30, 2021 | 2.27M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
2.27M
Minimum
2021
5.600M
Maximum
2023
3.595M
Average
3.255M
Median
Research and Development Expense (Annual) Benchmarks
| Lifecore Biomedical Inc | 8.575M |
| Ligand Pharmaceuticals Inc | 24.54M |
| Revance Therapeutics Inc | 79.41M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |